Marginal Zone Lymphoma
144
44
62
46
Key Insights
Highlights
Success Rate
67% trial completion
Published Results
37 trials with published results (26%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
16.0%
23 terminated out of 144 trials
66.7%
-19.8% vs benchmark
7%
10 trials in Phase 3/4
80%
37 of 46 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 46 completed trials
Clinical Trials (144)
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
Obinutuzumab in Marginal Zone Lymphoma
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
SynKIR-310 for Relapsed/Refractory B-NHL
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study